Insider sale details
Richard Giroux, who serves as both Chief Financial Officer and Chief Operating Officer of MeiraGTx Holdings plc (NASDAQ:MGTX), sold 56,000 ordinary shares of the company on April 21, 2026. The total proceeds from those transactions amounted to $572,320.
The shares changed hands at prices between $9.96 and $10.60, with a weighted average price of $10.22 per share. According to the filings, the disposals were carried out under a Rule 10b5-1 trading plan that Mr. Giroux adopted on November 18, 2025.
Context on ownership and recent share performance
After completing the sales, Mr. Giroux retains direct ownership of 971,530 ordinary shares. In addition to his direct holdings, he indirectly holds 5,152 ordinary shares through his spouse and 85,000 ordinary shares through Aigle Healthcare Partners III LLC.
The timing of the sale coincides with a difficult week for MeiraGTx stock, which fell 9.6% over the past week despite having gained 62% over the previous year.
Company valuation and market position
The company is described as a $925 million biotech that currently trades above its InvestingPro Fair Value, placing it on that platform’s list of most overvalued stocks. The InvestingPro service is cited as offering valuation metrics and additional insights for subscribers.
Recent corporate and clinical developments
MeiraGTx has priced a $100 million share offering at $9 per share. The company stated the proceeds are expected to support operating expenses and capital expenditure requirements into the second half of 2028. The filing notes that this funding could enable potential commercial launches of gene therapies, subject to regulatory approvals.
In a separate transaction, MeiraGTx reacquired the gene therapy botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson, agreeing to an upfront payment of $25 million plus future royalties.
On the clinical front, MeiraGTx reported positive three-year data from its Phase 1 AQUAx study in radiation-induced xerostomia, indicating sustained improvements in patient symptoms and saliva flow rates.
Analyst responses
Following the recent clinical and corporate moves, RBC Capital raised its price target for MeiraGTx to $24, citing the xerostomia data and the reacquisition of the XLRP program. H.C. Wainwright has maintained a Buy rating with a $20 price target, expressing confidence in the gene therapy programs.
Note: This article reports the transactions, holdings, corporate financing and clinical results as disclosed. It does not include additional commentary beyond the information provided in company filings and analyst notes cited.